Skip to main content

Table 3 Impact of COVID-19 on NMD

From: A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

  Without effect (n = 48)
No. (%)
Aggravating factor (n = 26)
No. (%)
Death (n = 9)
No. (%)
p value
Type of disease     0.716
 Myopathy 17 (63) 8 (29.6) 2 (7.4)  
 Neuropathy 15 (65.2) 6 (26.1) 2 (8.7)  
 Myasthenia 16 (48.5) 12 (36.4) 5(15.2)  
Origin of the disease     0.322
 Acquired 23 (53.5) 13 (30.2) 7 (16.3)  
 Genetic 24 (61.5) 13 (33.3) 2 (5.1)  
Severity of neuromuscular diseaseƗ     0.170
 Low 21 (70.0) 7 (23.3) 2 (6.7)  
 Moderate 19 (54.3) 13 (37.1) 3 (8.6)  
 High 6 (37.5) 6 (37.5) 4 (25.0)  
Mobility     0.110
 Walk 35 (61.4) 20 (35.1) 2 (3.5)  
 Walk with help 7 (58.3) 3 (25.0) 2 (16.7)  
 Wheelchair 6 (50.0) 3 (25.0) 3 (25.0)  
Gender     0.079
 Men 15 (44.1) 13 (38.2) 6 (17.6)  
 Women 33 (67.3) 13 (26.5) 3 (6.1)  
Age > 65 yrs old 9 (47.4) 8 (42.1) 2 (10.5) 0.553
Respiratory failure 13 (48.1) 10 (37.0) 4 (14.8) 0.233
Heart failure 12 (75.0) 3 (18.8) 1 (6.2) 0.401
Obesity 0 7 (87.5) 1 (12.5) 0.001*
Hypertension 4 (36.4) 4 (36.4) 3 (27.3) 0.097
Diabetes 2 (20.0) 3 (30.0) 5 (50.0)  < 0.001*
Corticosteroids,§ 9 (69.2) 2 (15.4) 2 (15.4) 0.394
Immunosuppressants other than corticosteroids,§ 9 (60.0) 5 (33.3) 1 (6.7) 0.565
  1. n number of cases, No. (%) number of cases (% of cases)
  2. ƗAccording to the physician
  3. Prior to COVID-19
  4. §Statistical analysis have been performed only on populations with acquired disease
  5. *p < 0.05 was statistically significant